Avion Vice President Woo Sungyun purchased 32,620 shares of the company’s common stock on the open market the previous day.


Avion Vice President Woo Sungyun Purchases 32,620 Shares on Open Market... "Commitment to Enhancing Shareholder Value" View original image

According to Avion on July 7, the number of shares held by Vice President Woo increased from 67,991 shares as of April 29 to 100,611 shares. His equity stake rose by 0.03 percentage points, from 0.08% to 0.11%.


The company stated that this open market purchase reflects confidence in the development achievements of its core pipeline and long-term growth potential. It further explained that, given the current share price does not fully reflect the company’s technology and pipeline value, this move demonstrates a commitment to enhancing both corporate value and shareholder value.


Avion is conducting global clinical trials for its non-small cell lung cancer drug candidate, Vavamekip (ABN401), and is also advancing next-generation antibody-interferon beta conjugate (iRAC) platform and antibody-based new drug development. The company aims to increase its mid- to long-term corporate value by advancing research and development on its key pipelines and expanding opportunities for global technology licensing (LO).



An Avion representative stated, “This share purchase reflects our confidence in the company’s technological competitiveness and the commercialization potential of our core pipeline,” adding, “We will do our utmost to continuously enhance corporate value and meet shareholder expectations through key development projects and achievements in global business development.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing